CN115475257A - Medical ultrasonic coupling agent and preparation method thereof - Google Patents
Medical ultrasonic coupling agent and preparation method thereof Download PDFInfo
- Publication number
- CN115475257A CN115475257A CN202211038221.9A CN202211038221A CN115475257A CN 115475257 A CN115475257 A CN 115475257A CN 202211038221 A CN202211038221 A CN 202211038221A CN 115475257 A CN115475257 A CN 115475257A
- Authority
- CN
- China
- Prior art keywords
- parts
- stirring
- modifier
- chitosan
- medical ultrasonic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007822 coupling agent Substances 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims description 41
- 239000003607 modifier Substances 0.000 claims abstract description 99
- 229920001661 Chitosan Polymers 0.000 claims abstract description 75
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 54
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 54
- -1 o-phthalaldehyde compound Chemical class 0.000 claims abstract description 46
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 39
- 229940054441 o-phthalaldehyde Drugs 0.000 claims abstract description 36
- 239000008367 deionised water Substances 0.000 claims abstract description 32
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 32
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 30
- 229910021389 graphene Inorganic materials 0.000 claims abstract description 30
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 22
- 229960001631 carbomer Drugs 0.000 claims abstract description 22
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 238000003756 stirring Methods 0.000 claims description 97
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 42
- 238000002156 mixing Methods 0.000 claims description 41
- 239000010456 wollastonite Substances 0.000 claims description 39
- 229910052882 wollastonite Inorganic materials 0.000 claims description 39
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 28
- 239000006185 dispersion Substances 0.000 claims description 24
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 21
- 239000011787 zinc oxide Substances 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 14
- 239000006087 Silane Coupling Agent Substances 0.000 claims description 14
- 238000001132 ultrasonic dispersion Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 8
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 7
- 229960000583 acetic acid Drugs 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 239000012362 glacial acetic acid Substances 0.000 claims description 7
- VQEHIYWBGOJJDM-UHFFFAOYSA-H lanthanum(3+);trisulfate Chemical compound [La+3].[La+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O VQEHIYWBGOJJDM-UHFFFAOYSA-H 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 235000010413 sodium alginate Nutrition 0.000 claims description 7
- 239000000661 sodium alginate Substances 0.000 claims description 7
- 229940005550 sodium alginate Drugs 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- 238000002604 ultrasonography Methods 0.000 claims 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 22
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 7
- 230000007547 defect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention relates to the technical field of ultrasonic coupling agents, and particularly discloses a medical ultrasonic coupling agent which comprises the following raw materials in parts by weight: 20-30 parts of carbomer, 10-15 parts of EDTA-2Na, 5-10 parts of chitosan modifier, 4-8 parts of o-phthalaldehyde compound modified antibacterial agent, 1-3 parts of sodium hydroxide, 35-45 parts of deionized water and 2-5 parts of glycerol. According to the ultrasonic coupling agent disclosed by the invention, carbomer is matched with EDTA-2Na, the chitosan modifier and the o-phthalaldehyde compound modified antibacterial agent are added for synergistic improvement, so that the antibacterial effect of the product is enhanced, and the chitosan in the chitosan modifier is modified by the graphene modifier, so that the stability of the o-phthalaldehyde compound modified antibacterial agent can be improved, the antibacterial performance and the antibacterial stability of the product are synergistically enhanced, and the antibacterial efficiency and the quality level are further improved.
Description
Technical Field
The invention relates to the technical field of coupling agents, in particular to a medical ultrasonic coupling agent and a preparation method thereof.
Background
The medical ultrasonic coupling agent mainly uses mineral oil (including vaseline and butter), vegetable oil, silicon oil and the like in the early stage, has poor acoustic characteristics, is difficult to obtain high-quality ultrasonic images, and has the defects of easy stimulation to skin, damage to a probe, dirt on clothes, difficult cleaning and the like. With the development of ultrasonic medicine, medical ultrasonic couplants are also continuously improved, the main components of the couplants are developed into carbomer resin, and the carbomer resin is prepared by adding a neutralizer, a humectant, a disinfectant, a preservative, a colorant, a stabilizer and the like, and the medical ultrasonic couplants can form high-viscosity gel at a very low concentration, so that the medical ultrasonic couplants are widely applied.
The existing medical ultrasonic coupling agent has poor sterilization efficiency and can not realize long-term sterilization effect, and on the basis, the invention further improves and optimizes the treatment.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a medical ultrasonic couplant and a preparation method thereof, so as to solve the problems in the background technology.
The technical scheme adopted by the invention for solving the technical problems is as follows:
the invention provides a medical ultrasonic coupling agent, which comprises the following raw materials in parts by weight:
20-30 parts of carbomer, 10-15 parts of EDTA-2Na, 5-10 parts of chitosan modifier, 4-8 parts of o-phthalaldehyde compound modified antibacterial agent, 1-3 parts of sodium hydroxide, 35-45 parts of deionized water and 2-5 parts of glycerol.
Preferably, the medical ultrasonic couplant comprises the following raw materials in parts by weight:
25 parts of carbomer, 12.5 parts of EDTA-2Na, 7.5 parts of chitosan modifier, 6 parts of o-phthalaldehyde compound modified antibacterial agent, 2 parts of sodium hydroxide, 40 parts of deionized water and 3.5 parts of glycerol.
Preferably, the preparation method of the chitosan modifier comprises the following steps:
s01: adding 10-20 parts of chitosan into 25-35 parts of deionized water, uniformly dispersing, then adding glacial acetic acid, and adjusting the pH value to 5.0 to obtain a chitosan dispersion liquid;
s02: adding 5-10 parts of graphene into 10-15 parts of hydrochloric acid solution, then adding 1-3 parts of sodium alkylsulfonate and 1-2 parts of citric acid, stirring and mixing fully, washing with water, and drying to obtain a graphene modifier;
s03: and stirring and mixing the graphene modifier and the chitosan dispersion liquid according to the weight ratio of 1:5, stirring at the rotating speed of 300-500r/min for 10-20min, and obtaining the chitosan modifier after stirring.
Preferably, the mass fraction of the hydrochloric acid solution is 5-10%.
Preferably, the rotation speed of the S02 for stirring and mixing is 500-1000r/min, and the stirring time is 20-30min.
The inventor of the invention finds that the antibacterial effect of the product is obviously reduced without adding a chitosan modifier, the stability is obviously reduced, the graphene modifier is not added in the preparation of the chitosan modifier, the antibacterial effect of the product is obviously changed, in addition, the graphene is adopted for replacing, and the chitosan dispersion liquid is not adopted for processing in the preparation of the chitosan modifier, so that the performance of the product has a variation trend, only the antibacterial effect of the chitosan modifier prepared by the method of the invention is most obvious, and the effect of the invention can not be realized by other methods;
preferably, the preparation method of the o-phthalaldehyde compound modified antibacterial agent comprises the following steps:
adding 10-20 parts of trichlorocarbaryl into 20-30 parts of deionized water, stirring and mixing uniformly, then adding wollastonite modifier and 2-5 parts of o-phthalaldehyde, and performing ultrasonic dispersion treatment to obtain an o-phthalaldehyde compound modified antibacterial agent; the preparation method of the wollastonite modifier comprises the following steps:
s11: adding 5-10 parts of zinc oxide into 20-30 parts of silane coupling agent solution, then adding 1-6 parts of lanthanum sulfate, and stirring and mixing fully to obtain zinc oxide solution;
s12: adding 3-6 parts of wollastonite into 10-20 parts of zinc oxide solution, uniformly dispersing and stirring, then adding 1-5 parts of sodium alginate, and fully stirring and mixing to obtain the wollastonite modifier.
The inventor finds that the wollastonite modifier is not added in the preparation of the o-phthalaldehyde compound modified antibacterial agent, and the wollastonite is not added in the preparation of the wollastonite modifier, so that the antibacterial stability of the product is obviously reduced, the wollastonite modifier of the product can play a synergistic effect with the chitosan modifier, the antibacterial stability effect of the product is enhanced together, and the antibacterial stability effect of the product is improved.
Preferably, the mass fraction of the silane coupling agent solution is 10-15%.
Preferably, the ultrasonic dispersion is sonicated at a power of 450-550W for 5-10min.
The invention also provides a preparation method of the medical ultrasonic coupling agent, which comprises the following steps:
step one, sequentially adding carbomer and EDTA-2Na into deionized water, and then adding glycerol to obtain a mixed material;
secondly, adding a chitosan modifier and an o-phthalaldehyde compound modified antibacterial agent, dispersing and stirring, and stirring fully;
and step three, finally adding sodium hydroxide, and adjusting the pH value to obtain the medical ultrasonic coupling agent.
Preferably, the rotation speed of the dispersion stirring treatment is 350-400r/min, and the stirring time is 20-30min.
Compared with the prior art, the invention has the following beneficial effects:
the ultrasonic couplant disclosed by the invention is prepared by matching carbomer with EDTA-2Na, performing synergistic improvement by adding a chitosan modifier and an o-phthalaldehyde compound modified antibacterial agent, and enhancing the antibacterial effect of a product, wherein chitosan in the chitosan modifier can be synergistically enhanced with the o-phthalaldehyde compound modified antibacterial agent after being modified by a graphene modifier, so that the antibacterial and antibacterial stability of the product is enhanced together, and the antibacterial efficiency is further improved.
Detailed Description
The technical solutions in the embodiments of the present invention are clearly and completely described below with reference to specific embodiments, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be obtained by a person skilled in the art without making any creative effort based on the embodiments in the present invention, belong to the protection scope of the present invention.
The medical ultrasonic couplant comprises the following raw materials in parts by weight:
20-30 parts of carbomer, 10-15 parts of EDTA-2Na, 5-10 parts of chitosan modifier, 4-8 parts of o-phthalaldehyde compound modified antibacterial agent, 1-3 parts of sodium hydroxide, 35-45 parts of deionized water and 2-5 parts of glycerol.
The medical ultrasonic couplant comprises the following raw materials in parts by weight:
25 parts of carbomer, 12.5 parts of EDTA-2Na, 7.5 parts of chitosan modifier, 6 parts of o-phthalaldehyde compound modified antibacterial agent, 2 parts of sodium hydroxide, 40 parts of deionized water and 3.5 parts of glycerol.
The preparation method of the chitosan modifier of the embodiment comprises the following steps:
s01: adding 10-20 parts of chitosan into 25-35 parts of deionized water, uniformly dispersing, then adding glacial acetic acid, and adjusting the pH value to 5.0 to obtain a chitosan dispersion liquid;
s02: adding 5-10 parts of graphene into 10-15 parts of hydrochloric acid solution, then adding 1-3 parts of sodium alkylsulfonate and 1-2 parts of citric acid, stirring and mixing fully, washing with water, and drying to obtain a graphene modifier;
s03: and stirring and mixing the graphene modifier and the chitosan dispersion liquid according to the weight ratio of 1:5, stirring at the rotating speed of 300-500r/min for 10-20min, and finishing stirring to obtain the chitosan modifier.
The mass fraction of the hydrochloric acid solution in this example is 5-10%.
In the embodiment, the rotation speed of the S02 is 500-1000r/min, and the stirring time is 20-30min.
The preparation method of the compound modified o-phthalaldehyde antibacterial agent comprises the following steps:
adding 10-20 parts of trichlorocarbaryl into 20-30 parts of deionized water, stirring and mixing uniformly, then adding wollastonite modifier and 2-5 parts of o-phthalaldehyde, and performing ultrasonic dispersion treatment to obtain an o-phthalaldehyde compound modified antibacterial agent; the preparation method of the wollastonite modifier comprises the following steps:
s11: adding 5-10 parts of zinc oxide into 20-30 parts of silane coupling agent solution, then adding 1-6 parts of lanthanum sulfate, and stirring and mixing fully to obtain zinc oxide solution;
s12: adding 3-6 parts of wollastonite into 10-20 parts of zinc oxide solution, uniformly dispersing and stirring, then adding 1-5 parts of sodium alginate, and fully stirring and mixing to obtain the wollastonite modifier.
The silane coupling agent solution of this example was 10 to 15 mass%.
The ultrasonic dispersion of this example was sonicated at a power of 450-550W for 5-10min.
The preparation method of the medical ultrasonic couplant comprises the following steps:
step one, sequentially adding carbomer and EDTA-2Na into deionized water, and then adding glycerol to obtain a mixed material;
secondly, adding a chitosan modifier and an o-phthalaldehyde compound modified antibacterial agent, dispersing and stirring, and stirring fully;
and step three, finally adding sodium hydroxide, and adjusting the pH value to obtain the medical ultrasonic coupling agent.
The rotation speed of the dispersion stirring treatment in the embodiment is 350-400r/min, and the stirring time is 20-30min.
Example 1.
The medical ultrasonic couplant comprises the following raw materials in parts by weight:
20 parts of carbomer, 10 parts of EDTA-2Na, 5 parts of chitosan modifier, 4 parts of phthalaldehyde compound modified antibacterial agent, 1 part of sodium hydroxide, 35 parts of deionized water and 2 parts of glycerol.
The preparation method of the chitosan modifier of the embodiment comprises the following steps:
s01: adding 10 parts of chitosan into 25 parts of deionized water, uniformly dispersing, then adding glacial acetic acid, and adjusting the pH value to 5.0 to obtain a chitosan dispersion liquid;
s02: adding 5 parts of graphene into 10 parts of hydrochloric acid solution, then adding 1 part of sodium alkylsulfonate and 1 part of citric acid, stirring and mixing fully, washing with water, and drying to obtain a graphene modifier;
s03: and stirring and mixing the graphene modifier and the chitosan dispersion liquid according to the weight ratio of 1:5, stirring at the rotating speed of 300r/min for 10min, and obtaining the chitosan modifier after stirring.
The mass fraction of the hydrochloric acid solution in this example was 5%.
In the embodiment, the rotation speed for fully stirring and mixing S02 is 500r/min, and the stirring time is 20min.
The preparation method of the compound modified o-phthalaldehyde antibacterial agent comprises the following steps:
adding 10 parts of trichlorocarbaryl into 20 parts of deionized water, stirring and mixing uniformly, then adding wollastonite modifier and 3.5 parts of o-phthalaldehyde, and performing ultrasonic dispersion treatment to obtain an o-phthalaldehyde compound modified antibacterial agent; the preparation method of the wollastonite modifier comprises the following steps:
s11: adding 5 parts of zinc oxide into 20 parts of silane coupling agent solution, then adding 1 part of lanthanum sulfate, and stirring and mixing fully to obtain zinc oxide solution;
s12: and adding 3 parts of wollastonite into 10 parts of zinc oxide solution, uniformly dispersing and stirring, then adding 1 part of sodium alginate, and fully stirring and mixing to obtain the wollastonite modifier.
The silane coupling agent solution of this example was 10% by mass.
The ultrasonic dispersion of this example was subjected to ultrasonic treatment at a power of 450W for 5min.
The preparation method of the medical ultrasonic couplant comprises the following steps:
step one, sequentially adding carbomer and EDTA-2Na into deionized water, and then adding glycerol to obtain a mixed material;
secondly, adding a chitosan modifier and an o-phthalaldehyde compound modified antibacterial agent, dispersing and stirring, and stirring fully;
and step three, finally adding sodium hydroxide, and adjusting the pH value to obtain the medical ultrasonic coupling agent.
The rotation speed of the dispersion stirring treatment in this example was 350r/min, and the stirring time was 20min.
Example 2.
The medical ultrasonic couplant comprises the following raw materials in parts by weight:
30 parts of carbomer, 15 parts of EDTA-2Na, 10 parts of chitosan modifier, 8 parts of phthalaldehyde compound modified antibacterial agent, 3 parts of sodium hydroxide, 45 parts of deionized water and 5 parts of glycerol.
The preparation method of the chitosan modifier of the embodiment comprises the following steps:
s01: adding 20 parts of chitosan into 35 parts of deionized water, uniformly dispersing, then adding glacial acetic acid, and adjusting the pH value to 5.0 to obtain a chitosan dispersion liquid;
s02: adding 10 parts of graphene into 15 parts of hydrochloric acid solution, then adding 3 parts of sodium alkylsulfonate and 2 parts of citric acid, stirring and mixing fully, washing with water, and drying to obtain a graphene modifier;
s03: and stirring and mixing the graphene modifier and the chitosan dispersion liquid according to a weight ratio of 1:5, stirring at a rotating speed of 500r/min for 20min, and obtaining the chitosan modifier after stirring.
The mass fraction of the hydrochloric acid solution in this example was 10%.
In the embodiment, the rotation speed for fully stirring and mixing S02 is 1000r/min, and the stirring time is 30min.
The preparation method of the compound modified o-phthalaldehyde antibacterial agent comprises the following steps:
adding 20 parts of trichlorocarbaryl into 30 parts of deionized water, stirring and mixing uniformly, then adding wollastonite modifier and 3.5 parts of o-phthalaldehyde, and performing ultrasonic dispersion treatment to obtain an o-phthalaldehyde compound modified antibacterial agent; the preparation method of the wollastonite modifier comprises the following steps:
s11: adding 10 parts of zinc oxide into 30 parts of silane coupling agent solution, then adding 6 parts of lanthanum sulfate, and stirring and mixing fully to obtain zinc oxide solution;
s12: adding 6 parts of wollastonite into 20 parts of zinc oxide solution, uniformly dispersing and stirring, then adding 5 parts of sodium alginate, and fully stirring and mixing to obtain the wollastonite modifier.
The silane coupling agent solution of this example was 15% by mass.
The ultrasonic dispersion of the present embodiment was subjected to ultrasonic treatment at a power of 550W for 10min.
The preparation method of the medical ultrasonic couplant comprises the following steps:
step one, sequentially adding carbomer and EDTA-2Na into deionized water, and then adding glycerol to obtain a mixed material;
secondly, adding a chitosan modifier and an o-phthalaldehyde compound modified antibacterial agent, dispersing and stirring, and stirring fully;
and step three, finally adding sodium hydroxide, and adjusting the pH value to obtain the medical ultrasonic coupling agent.
The rotation speed of the dispersion stirring treatment in this example was 400r/min, and the stirring time was 30min.
Example 3.
The medical ultrasonic couplant comprises the following raw materials in parts by weight:
25 parts of carbomer, 12.5 parts of EDTA-2Na, 7.5 parts of chitosan modifier, 6 parts of o-phthalaldehyde compound modified antibacterial agent, 2 parts of sodium hydroxide, 40 parts of deionized water and 3.5 parts of glycerol.
The preparation method of the chitosan modifier of the embodiment comprises the following steps:
s01: adding 15 parts of chitosan into 30 parts of deionized water, uniformly dispersing, then adding glacial acetic acid, and adjusting the pH value to 5.0 to obtain a chitosan dispersion liquid;
s02: adding 7.5 parts of graphene into 12.5 parts of hydrochloric acid solution, then adding 2 parts of sodium alkylsulfonate and 1.5 parts of citric acid, stirring and mixing fully, washing with water, and drying to obtain a graphene modifier;
s03: and stirring and mixing the graphene modifier and the chitosan dispersion liquid according to a weight ratio of 1:5, stirring for 15min at a rotating speed of 400r/min, and finishing stirring to obtain the chitosan modifier.
The mass fraction of the hydrochloric acid solution in this example was 7.5%.
In the embodiment, the rotation speed for fully stirring and mixing S02 is 750r/min, and the stirring time is 25min.
The preparation method of the compound modified o-phthalaldehyde antibacterial agent comprises the following steps:
adding 15 parts of trichlorocarbaryl into 25 parts of deionized water, stirring and mixing uniformly, then adding a wollastonite modifier and 3.5 parts of o-phthalaldehyde, and performing ultrasonic dispersion treatment to obtain an o-phthalaldehyde compound modified antibacterial agent; the preparation method of the wollastonite modifier comprises the following steps:
s11: adding 7.5 parts of zinc oxide into 25 parts of silane coupling agent solution, then adding 3.5 parts of lanthanum sulfate, and stirring and mixing fully to obtain zinc oxide solution;
s12: adding 4.5 parts of wollastonite into 15 parts of zinc oxide solution, uniformly dispersing and stirring, then adding 3 parts of sodium alginate, and fully stirring and mixing to obtain the wollastonite modifier.
The mass fraction of the silane coupling agent solution of this example was 12.5%.
The ultrasonic dispersion of this example was sonicated at a power of 500W for 7.5min.
The preparation method of the medical ultrasonic couplant comprises the following steps:
step one, sequentially adding carbomer and EDTA-2Na into deionized water, and then adding glycerol to obtain a mixed material;
secondly, adding a chitosan modifier and an o-phthalaldehyde compound modified antibacterial agent, dispersing and stirring, and stirring fully;
and step three, finally adding sodium hydroxide, and adjusting the pH value to obtain the medical ultrasonic coupling agent.
The rotation speed of the dispersion stirring treatment in this example was 370r/min, and the stirring time was 25min.
Example 4.
The medical ultrasonic couplant comprises the following raw materials in parts by weight:
22 parts of carbomer, 12 parts of EDTA-2Na, 6 parts of chitosan modifier, 5 parts of phthalaldehyde compound modified antibacterial agent, 2 parts of sodium hydroxide, 36 parts of deionized water and 3 parts of glycerol.
The preparation method of the chitosan modifier of the embodiment comprises the following steps:
s01: adding 12 parts of chitosan into 26 parts of deionized water, uniformly dispersing, then adding glacial acetic acid, and adjusting the pH value to 5.0 to obtain a chitosan dispersion liquid;
s02: adding 6 parts of graphene into 12 parts of hydrochloric acid solution, then adding 2 parts of sodium alkylsulfonate and 1.2 parts of citric acid, stirring and mixing fully, washing with water, and drying to obtain a graphene modifier;
s03: and (3) stirring and mixing the graphene modifier and the chitosan dispersion liquid according to the weight ratio of 1:5, stirring at the rotating speed of 350r/min for 12min, and obtaining the chitosan modifier after stirring.
The mass fraction of the hydrochloric acid solution in this example was 6%.
In the embodiment, the rotation speed for fully stirring and mixing S02 is 650r/min, and the stirring time is 22min.
The preparation method of the compound modified o-phthalaldehyde antibacterial agent comprises the following steps:
adding 12 parts of trichlorocarbaryl into 22 parts of deionized water, stirring and mixing uniformly, then adding a wollastonite modifier and 3.5 parts of o-phthalaldehyde, and performing ultrasonic dispersion treatment to obtain an o-phthalaldehyde compound modified antibacterial agent; the preparation method of the wollastonite modifier comprises the following steps:
s11: adding 6 parts of zinc oxide into 22 parts of silane coupling agent solution, then adding 2 parts of lanthanum sulfate, and stirring and mixing fully to obtain zinc oxide solution;
s12: adding 4 parts of wollastonite into 12 parts of zinc oxide solution, uniformly dispersing and stirring, then adding 2 parts of sodium alginate, and fully stirring and mixing to obtain the wollastonite modifier.
The mass fraction of the silane coupling agent solution of this example was 12%.
The ultrasonic dispersion of this example was sonicated at 460W for 6min.
The preparation method of the medical ultrasonic couplant comprises the following steps:
step one, sequentially adding carbomer and EDTA-2Na into deionized water, and then adding glycerol to obtain a mixed material;
secondly, adding a chitosan modifier and an o-phthalaldehyde compound modified antibacterial agent, dispersing and stirring, and stirring fully;
and step three, finally adding sodium hydroxide, and adjusting the pH value to obtain the medical ultrasonic coupling agent.
The rotation speed of the dispersion stirring treatment in this example was 360r/min, and the stirring time was 22min.
Comparative example 1.
Unlike example 3, no chitosan modifier was added.
Comparative example 2.
Different from the embodiment 3, the graphene modifier is not added in the preparation of the chitosan modifier.
Comparative example 3.
The difference from example 3 is that the graphene modifier is replaced by graphene.
Comparative example 4.
The difference from example 3 is that the chitosan modifier was prepared without treatment with chitosan dispersion.
Comparative example 5.
Different from the embodiment 3, the method does not add wollastonite modifier in the preparation of the o-phthalaldehyde compound modified antibacterial agent.
Comparative example 6.
Different from the example 3, the wollastonite modifier is not added in the preparation of the wollastonite modifier.
The results of the performance measurements of examples 1 to 4 and comparative examples 1 to 6 are as follows
It can be seen from examples 1-4 and comparative examples 1-6 that the product of example 3 has excellent antibacterial properties and antibacterial stability;
it can be seen from comparative examples 1 to 4 that the antibacterial effect of the product is significantly reduced without adding the chitosan modifier, and the stability is significantly reduced, the graphene modifier is not added in the preparation of the chitosan modifier, the antibacterial effect of the product is significantly changed, in addition, the graphene is used for substitution, and the chitosan dispersion liquid is not used for treatment in the preparation of the chitosan modifier, so that the performance of the product tends to be deteriorated, only the chitosan modifier prepared by the method of the present invention has the most significant antibacterial effect, and the effect of the present invention cannot be realized by other methods;
it can be seen from comparative examples 5-6 that the wollastonite modifier is not added in the preparation of the o-phthalaldehyde compound modified antibacterial agent and the wollastonite is not added in the preparation of the wollastonite modifier, so that the antibacterial stability of the product is remarkably reduced, the wollastonite modifier of the product can play a role in coordination and synergism with the chitosan modifier, the antibacterial stability effect of the product is enhanced together, and the antibacterial stability effect of the product is improved.
It will be evident to those skilled in the art that the invention is not limited to the details of the foregoing illustrative embodiments, and that the present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.
Furthermore, it should be understood that although the present description refers to embodiments, not every embodiment may contain only a single embodiment, and such description is for clarity only, and those skilled in the art should integrate the description, and the embodiments may be combined as appropriate to form other embodiments understood by those skilled in the art.
Claims (10)
1. The medical ultrasonic couplant is characterized by comprising the following raw materials in parts by weight:
20-30 parts of carbomer, 10-15 parts of EDTA-2Na, 5-10 parts of chitosan modifier, 4-8 parts of phthalaldehyde compound modified antibacterial agent, 1-3 parts of sodium hydroxide, 35-45 parts of deionized water and 2-5 parts of glycerol.
2. The medical ultrasonic couplant of claim 1, wherein the medical ultrasonic couplant comprises the following raw materials in parts by weight:
25 parts of carbomer, 12.5 parts of EDTA-2Na, 7.5 parts of chitosan modifier, 6 parts of o-phthalaldehyde compound modified antibacterial agent, 2 parts of sodium hydroxide, 40 parts of deionized water and 3.5 parts of glycerol.
3. The medical ultrasonic couplant of claim 1, wherein the chitosan modifier is prepared by a method comprising the following steps:
s01: adding 10-20 parts of chitosan into 25-35 parts of deionized water, uniformly dispersing, then adding glacial acetic acid, and adjusting the pH value to 5.0 to obtain a chitosan dispersion liquid;
s02: adding 5-10 parts of graphene into 10-15 parts of hydrochloric acid solution, then adding 1-3 parts of sodium alkylsulfonate and 1-2 parts of citric acid, stirring and mixing fully, washing with water, and drying to obtain a graphene modifier;
s03: and stirring and mixing the graphene modifier and the chitosan dispersion liquid according to the weight ratio of 1:5, stirring at the rotating speed of 300-500r/min for 10-20min, and finishing stirring to obtain the chitosan modifier.
4. The medical ultrasonic couplant of claim 3, wherein the mass fraction of the hydrochloric acid solution is 5-10%.
5. The medical ultrasonic couplant of claim 3, wherein the rotation speed of the S02 stirring and mixing is 500-1000r/min, and the stirring time is 20-30min.
6. The medical ultrasonic couplant of claim 1, wherein the preparation method of the phthalaldehyde compound modified antibacterial agent comprises the following steps:
adding 10-20 parts of trichlorocarbaryl into 20-30 parts of deionized water, stirring and mixing uniformly, then adding wollastonite modifier and 2-5 parts of o-phthalaldehyde, and performing ultrasonic dispersion treatment to obtain an o-phthalaldehyde compound modified antibacterial agent; the preparation method of the wollastonite modifier comprises the following steps:
s11: adding 5-10 parts of zinc oxide into 20-30 parts of silane coupling agent solution, then adding 1-6 parts of lanthanum sulfate, and stirring and mixing fully to obtain zinc oxide solution;
s12: adding 3-6 parts of wollastonite into 10-20 parts of zinc oxide solution, uniformly dispersing and stirring, then adding 1-5 parts of sodium alginate, and fully stirring and mixing to obtain the wollastonite modifier.
7. The medical ultrasonic couplant of claim 6, wherein the mass fraction of the silane coupling agent solution is 10-15%.
8. The medical ultrasonic couplant of claim 6, wherein the ultrasonic dispersion is performed for 5-10min at a power of 450-550W.
9. A method for preparing a medical ultrasound couplant as claimed in any one of claims 1 to 8, comprising the steps of:
step one, sequentially adding carbomer and EDTA-2Na into deionized water, and then adding glycerol to obtain a mixed material;
secondly, adding a chitosan modifier and an o-phthalaldehyde compound modified antibacterial agent, dispersing and stirring, and stirring fully;
and step three, finally adding sodium hydroxide, and adjusting the pH value to obtain the medical ultrasonic coupling agent.
10. The method for preparing a medical ultrasound couplant according to claim 9, wherein the rotational speed of the dispersion stirring treatment is 350-400r/min, and the stirring time is 20-30min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211038221.9A CN115475257A (en) | 2022-08-29 | 2022-08-29 | Medical ultrasonic coupling agent and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211038221.9A CN115475257A (en) | 2022-08-29 | 2022-08-29 | Medical ultrasonic coupling agent and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115475257A true CN115475257A (en) | 2022-12-16 |
Family
ID=84422948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211038221.9A Pending CN115475257A (en) | 2022-08-29 | 2022-08-29 | Medical ultrasonic coupling agent and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115475257A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116217081A (en) * | 2023-05-09 | 2023-06-06 | 广东特地陶瓷有限公司 | Antibacterial ceramic glaze and preparation method and application thereof |
| CN117679537A (en) * | 2024-02-04 | 2024-03-12 | 山东消博士消毒科技股份有限公司 | Medical sterile ultrasonic coupling agent and preparation method thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030104020A1 (en) * | 2001-11-09 | 2003-06-05 | Davison Gordon Robert | Chitosan compositions |
| CN102512696A (en) * | 2011-12-31 | 2012-06-27 | 戴新春 | Medical ultrasonic couplant and preparation method thereof |
| CN102580121A (en) * | 2012-03-06 | 2012-07-18 | 江苏壹叁玖医疗器械有限公司 | Medical disinfection coupling agent |
| CN102716503A (en) * | 2012-06-04 | 2012-10-10 | 周郗竹 | Medical ultrasonic coupling agent and preparation method thereof |
| CN103007305A (en) * | 2013-01-04 | 2013-04-03 | 山西康灵医疗器械有限公司 | Preparation method of transparent bactericidal medical ultrasonic coupling agent |
| CN104483364A (en) * | 2014-12-03 | 2015-04-01 | 上海应用技术学院 | Graphene/SDS (Sodium Dodecyl Sulfate)-modified carbon paste electrode and preparation method thereof |
| CN113069561A (en) * | 2021-06-04 | 2021-07-06 | 广州市一杰医药科技有限公司 | Medical ultrasonic coupling agent with disinfection function and preparation method thereof |
| WO2022067960A1 (en) * | 2020-09-30 | 2022-04-07 | 南京信朗企业管理咨询有限公司 | Rinse-free hand-care antimicrobial gel and preparation method therefor |
-
2022
- 2022-08-29 CN CN202211038221.9A patent/CN115475257A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030104020A1 (en) * | 2001-11-09 | 2003-06-05 | Davison Gordon Robert | Chitosan compositions |
| CN102512696A (en) * | 2011-12-31 | 2012-06-27 | 戴新春 | Medical ultrasonic couplant and preparation method thereof |
| CN102580121A (en) * | 2012-03-06 | 2012-07-18 | 江苏壹叁玖医疗器械有限公司 | Medical disinfection coupling agent |
| CN102716503A (en) * | 2012-06-04 | 2012-10-10 | 周郗竹 | Medical ultrasonic coupling agent and preparation method thereof |
| CN103007305A (en) * | 2013-01-04 | 2013-04-03 | 山西康灵医疗器械有限公司 | Preparation method of transparent bactericidal medical ultrasonic coupling agent |
| CN104483364A (en) * | 2014-12-03 | 2015-04-01 | 上海应用技术学院 | Graphene/SDS (Sodium Dodecyl Sulfate)-modified carbon paste electrode and preparation method thereof |
| WO2022067960A1 (en) * | 2020-09-30 | 2022-04-07 | 南京信朗企业管理咨询有限公司 | Rinse-free hand-care antimicrobial gel and preparation method therefor |
| CN113069561A (en) * | 2021-06-04 | 2021-07-06 | 广州市一杰医药科技有限公司 | Medical ultrasonic coupling agent with disinfection function and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 杨华明 易滨主编: "《现代医院消毒学第3版》", 人民军医出版社, pages: 168 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116217081A (en) * | 2023-05-09 | 2023-06-06 | 广东特地陶瓷有限公司 | Antibacterial ceramic glaze and preparation method and application thereof |
| CN116217081B (en) * | 2023-05-09 | 2023-07-25 | 广东特地陶瓷有限公司 | Antibacterial ceramic glaze and preparation method and application thereof |
| CN117679537A (en) * | 2024-02-04 | 2024-03-12 | 山东消博士消毒科技股份有限公司 | Medical sterile ultrasonic coupling agent and preparation method thereof |
| CN117679537B (en) * | 2024-02-04 | 2024-04-30 | 山东消博士消毒科技股份有限公司 | Medical sterile ultrasonic coupling agent and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115475257A (en) | Medical ultrasonic coupling agent and preparation method thereof | |
| CN104721069B (en) | A kind of deep composition for hair dying of increasing | |
| CN115109513B (en) | Water-based single-component antibacterial child white board paint and preparation method thereof | |
| CN114989244A (en) | Bird's nest small-molecule peptide and preparation method and application thereof | |
| CN106109264B (en) | A kind of facial treatment mask and preparation method thereof with anti-bacteria wet keeping function | |
| CN106750584A (en) | A kind of method of the composite modified natural rubber masterbatch of lignin silica | |
| CN104188862B (en) | A kind of skin care scrub cream and preparation method thereof | |
| CN116586043A (en) | Preparation method and application of alginic acid composite gel | |
| CN104998304A (en) | Medical lubricating agent and preparation method thereof | |
| CN117402680A (en) | Special decontamination cleaning agent for aviation | |
| CN116407483A (en) | Formula and preparation method of oil-control moisturizing facial cleanser | |
| CN107164828A (en) | The preparation method of corn gluten protein modified function fiber | |
| CN115607464A (en) | Antibacterial stain-removing toothpaste and preparation method thereof | |
| CN107753961A (en) | A kind of Color Sonography ultrasonic coupling agent | |
| CN102256590B (en) | Cosmetic composition containing a locust bean gum hydrolysate | |
| CN117679537B (en) | Medical sterile ultrasonic coupling agent and preparation method thereof | |
| CN112640915A (en) | Preparation method of organic disinfectant based on cyclodextrin modification | |
| WO2019109646A1 (en) | Preparation method for chitosan-allantoin regenerated cellulose fibers | |
| CN111358706A (en) | Preparation method of alcohol-fibroin gel washing-free disinfectant | |
| CN116994794B (en) | Conductive silver paste composition based on nano modified particles and preparation method thereof | |
| CN111685277A (en) | Method for improving gel quality of fermented sausage | |
| WO2023125790A1 (en) | Cationized hyaluronic acid or salt thereof, and preparation method therefor | |
| CN115304990B (en) | Leather coating agent with lasting luster and preparation method thereof | |
| CN114606068B (en) | Thickening method and thickening formula of fatty alcohol polyoxyethylene ether sodium sulfate | |
| JP3016679B2 (en) | Noodles quality improver and noodles with improved texture |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |